1. Тактика выявления частых и редких типов химерного транскрипта BCR-ABL при хроническом миелоидном лейкозе / О. В. Никулина [и др.] // Клин. онкогематология. Фундам. исслед. и клин. практика. - 2015. - Т. 8, № 2. - С. 161-168.
2. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors / L. Falchi [et al.] // Am. J. Hematol. - 2013. - Vol. 88, N 12. - P. 1024-1029. https://doi. org/10.1002/ajh.23560
3. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program / J. Gabert [et al.] // Leukemia. - 2003. - Vol. 17, N 12. - P. 2318-2357. https://doi.org/10.1038/sj.leu.2403135
4. European Leukemia Net recommendations for the management of chronic myeloid leukemia / M. Baccarani [et al.] // Blood. - 2013. - Vol. 122, N 6. - P. 872-884. https://doi.org/10.1182/blood-2013-05-501569
5. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in Imatinib-treated chronic myeloid leukemia patients / I. Iacobucci [et al.] // Clin. Cancer Res. - 2006. - Vol. 12, N 10. - P. 3037-3042. https://doi.org/10.1158/1078-0432.ccr-05-2574
6. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with Imatinib Mesylate / J. Cortes [et al.] // Clin. Cancer Res. - 2005. - Vol. 11, N 9. - P. 3425-3432. https://doi.org/10.1158/1078-0432.ccr-04-2139
7. Куцев, С. И. Значение анализа мутаций гена BCR-ABL в оптимизации таргетной терапии хронического миелолейкоза / С. И. Куцев, М. В. Вельченко // Клин. онкогематология. Фундам. исслед. и клин. практика. - 2008. - Т. 1, № 3. - С. 190-199.
8. Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project / J. W. W. Coebergh [et al.] // Eur. J. Cancer. - 2006. - Vol. 42, N 13. - P. 2019-2036. https://doi.org/10.1016/j.ejca.2006.06.005
9. Suttorp, M. Chronic myeloid leukemia in children: diagnostics and management / M. Suttorp, J. Tabea Tauer, F. Millot // Third midsummer meeting on pediatric hematology and oncology, 10-12 June, Liberec / Department of Paediatric Haematology and Oncology [et al.]. - Prague, 2011. - P. 12-13.
10. Three decades of transplantation for chronic myeloid leukemia: what have we learned? / J. Pavlu [et al.] // Blood. - 2011. - Vol. 117, N 3. - P. 755-763. https://doi.org/10.1182/blood-2010-08-301341
11. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial / F.-X. Mahon [et al.] // Lancet Oncol. - 2010. - Vol. 11, N 11. - P. 1029-1035. https://doi.org/10.1016/s1470-2045(10)70233-3
12. Suttorp, M. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation / M. Suttorp, F. Millot // Hematology. - 2010. - Vol. 2010, N 1. - P. 368-376. https://doi.org/10.1182/ asheducation-2010.1.368
13. Wei, G. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib / G. Wei, S. Rafiyath, D. Liu // J. Hematol. Oncol. - 2010. - Vol. 3, N 1. - Art. 47. https://doi.org/10.1186/1756-8722-3-47
14. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-Paed I / M. Suttorp [et al.] // Klinische Pädiatrie. - 2009. - Vol. 221, N 6. - P. 351-357. https://doi.org/10.1055/ s-0029-1239529
15. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias / C. GambacortiPasserini [et al.] // Lancet Oncol. - 2003. - Vol. 4, N 2. - P. 75-85. https://doi.org/10.1016/s1470-2045(03)00979-3
16. Management and clinical outcome of CML patients after imatinib resistance associated with ABL kinase domain mutations / S. Kreill [et al.] // Blood. - 2003. - Vol. 102, N 11. - P. 71A.
17. Shah, N. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemia / N. Shah, C. Sawyers // Oncogene. - 2003. - Vol. 22, N 47. - P. 7389-7395. https://doi.org/10.1038/sj.onc.1206942
18. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib / H.-K. Al-Ali [et al.] // Hematology. - 2004. - Vol. 5, N 1. - P. 55-60. https://doi.org/10.1038/sj.thj.6200319
19. Hochhaus, A. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance / A. Hochhaus, P. La Rosée // Leukemia. - 2004. - Vol. 18, N 8. - P. 1321-1331. https://doi.org/10.1038/sj.leu.2403426
20. Branford, S. Chronic myeloid leukemia: molecular monitoring in clinical practice / S. Branford // Hematology. - 2007. - Vol. 2007, N 1. - P. 376-383. https://doi.org/10.1182/asheducation-2007.1.376
21. Correlation of BCR/ABL transcript variants with patients characteristics in childhood chronic myeloid leukaemia / R. Adler [et al.] // Eur. J. Haematol. - 2009. - Vol. 82, N 2. - P. 112-118. https://doi.org/10.1111/j.1600-0609.2008.01170.x
Послать статью по эл. почте 